B+
Bull case
0%
Probability
Target price
$30.50
+19.4% vs current
PFE
PfizerCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
1%
Probability
Target price
$27.75
+8.6% vs current
B-
Bear case
0%
Probability
Target price
$22.00
-13.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+55.6
Score
AI commentary
T+3 sentiment is mildly positive but still monitoring-style. The primary-source earnings release was supportive, and trusted post-print coverage indicated the stock rose more than 2% early on May 5 after the beat/reaffirmation, but the tone was tempered by commentary that a fuller growth recovery may take several years. Analyst revision visibility remains thin in the checked evidence, and no usable social-coverage signal was provided, so confidence should remain moderate rather than high.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-20eventQ1 beat and full-year 2026 guidance reaffirmation reset the post-print baselineMedium impact
Pfizer's May 5 earnings release reported Q1 2026 revenue of $14.451B, adjusted EPS of $0.75, and reaffirmed 2026 guidance of $59.5B-$62.5B revenue and $2.80-$3.00 adjusted EPS, which supports a near-term stabilization case after the print [#8-K-2026-05-05].
2026-08-03catalystLaunched and acquired product growth is the key bridge through COVID erosion and the coming LOE gapHigh impact
Primary-source Q1 results showed 22% operational growth from launched and acquired products and 7% operational growth ex-Comirnaty/Paxlovid, led by Padcev, Eliquis, oncology biosimilars, Nurtec, Lorbrena and Abrysvo, partially offset by Comirnaty down 59% operationally and Paxlovid down 63% operationally [#8-K-2026-05-05].
2026-12-31catalystPipeline readouts and pivotal-study cadence remain the main medium-term rerating leverHigh impact
Pfizer's Q1 2026 earnings materials highlighted positive Phase 3 and mid-stage readouts, pipeline momentum in oncology and obesity, and a plan to start about 20 key pivotal studies in 2026, keeping development execution as the main medium-term upside lever even if revenue recovery is back-end loaded.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology